Clinical trial on combined therapy for COPD: Triple better than double
A number of pharmaceuticals are available for COPD treatment. The ETHOS trial – headed by Prof. Klaus F. Rabe – compared combinations with two and three of them.
A number of pharmaceuticals are available for COPD treatment. The ETHOS trial – headed by Prof. Klaus F. Rabe – compared combinations with two and three of them.
A research team from Hannover with participation of the DZL have published a study on molecular markers for various forms of pulmonary hypertension in the American Journal of Pathology.
A successfully treated case at the Marburg University Medical Center is raising hope for a COVID-19 cure: The team has successfully used the cancer drug ruxolitinib for the first time to cure a patient suffering...
With the participation of Prof. Dr. Hans-Ulrich Kauczor, DZL board member, the World Health Organization (WHO) has published advisory guidelines for the application of imaging techniques in COVID-19, the lung disease caused by the coronavirus.
The collaborative research center 1213 for cardiopulmonary research in Giessen, spear-headed by DZL scientist Prof. Dr. Norbert Weissmann, will be funded by the German Re-search Foundation (DFG) for another four years. The first funding period...
Work group of DZL researcher identifies target molecule for the treatment of chronic obstructive pulmonary disease (COPD).
Lung cancer is the leading cause of cancer death for both men and women and accounts for almost 28% of all cancer deaths worldwide.
DZL researcher secures European funding in the amount of 1.1 million euros for joint project on the research of interstitial lung diseases.
An international team led by DZL researcher Dr. Danny Jonigk has been able to prove changes in the lung tissue caused by SARS-CoV-2. The findings of the study show a funda-mental difference to lung damage...
The rapid spreading of the novel coronavirus SARS-COV-2 in Germany and all over the world also affects the work of the German Center for Lung Research (DZL).
Researchers from the U.S. and Europe have found out that the coronavirus SARS-COV-2 en-ters the body probably mainly via two types of nasal mucosa cells. However, the findings of the present study also indicate that...
Research groups of the Charité – University Medicine in Berlin and in Heidelberg have succeeded in tracking the development of pulmonary fibrosis in detail.
